• Sign In
  • Home
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
  • Policy
  • Opinion
    • Editorials
    • Op-Eds
  • In Focus
  • Restoring America
  • Magazine
  • Watch
  • Sponsored
    • Examining Tax Reform
    • Fix TSCA
    • National Parks
    • Inside the Corn Belt
  • TWS Archive
Search
LogoWashington Examiner
Subscribe
LogoWashington Examiner
Sign in
Subscribe
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Entertainment
    • Washington Secrets
    • Sports
  • Policy
    • Defense
    • National Security
    • Energy and Environment
    • Education
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space
  • Trump Administration
  • IN FOCUS
  • Opinion
    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds
  • Restoring America
    • Patriotism & Unity
    • Faith, Freedom & Self-Reliance
    • Courage, Strength & Optimism
    • Equality, Not Elitism
    • Community & Family
    • Fairness & Justice
    • Mission
  • Watch
  • Magazine
    • Magazine
    • Quarterly Briefing
    • Archives
    • Games
  • Sponsored
    • National Parks
    • Examining Tax Reform
    • Fix TSCA
    • Inside the Corn Belt
  • Newsletters
More
    Home Authors Posts by Linda Johnson

    Linda Johnson

    Nonprescription Nexium heartburn medicine launches
    Business

    Nonprescription Nexium heartburn medicine launches

    Linda Johnson -
    May 27, 2014 6:28 pm
    0
    Pfizer ups offer for AstraZeneca again, to $119B
    Business

    Pfizer ups offer for AstraZeneca again, to $119B

    Linda Johnson -
    May 19, 2014 4:06 am
    0
    Pfizer seeks early approval for breast cancer drug
    Business

    Pfizer seeks early approval for breast cancer drug

    Linda Johnson -
    May 16, 2014 5:54 pm
    0
    Merck: New drugs pending approval or in late tests
    Business

    Merck: New drugs pending approval or in late tests

    Linda Johnson -
    May 6, 2014 11:02 pm
    0
    In this photo taken July 6, 2009 worker Roland Ulbrich presents an Aspirin pill made for Italy at the pharmaceutical plant of the Bayer Bitterfeld company in Bitterfeld-Wolfen, eastern Germany.  Germany's Bayer AG says it plans to buy U.S. pharmaceutical company Merck & Co. Inc.'s consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for US$ 14.2 billion. (AP Photo/Eckehard Schulz)
    Business

    Bayer to buy Merck consumer business for $14.2B

    Linda Johnson -
    May 6, 2014 7:29 pm
    0
    Pfizer 1Q profit drops 15 pct due to lower sales
    Business

    Pfizer 1Q profit drops 15 pct due to lower sales

    Linda Johnson -
    May 5, 2014 6:44 pm
    0
    Pfizer mulls options after AstraZeneca snubs offer
    Business

    Pfizer mulls options after AstraZeneca snubs offer

    Linda Johnson -
    May 5, 2014 5:57 pm
    0
    J&J: Business doing well on new product approvals
    Business

    J&J: Business doing well on new product approvals

    Linda Johnson -
    April 24, 2014 8:27 pm
    0
    FILE - This April 20, 2010 file photo, shows the exterior view of Amgen Inc. in Fremont, Calif. Amgen reports quarterly earnings on Tuesday, April 22, 2014. (AP Photo/Paul Sakuma, File)
    Business

    Amgen misses 1Q views as higher costs cut profit

    Linda Johnson -
    April 22, 2014 11:13 pm
    0
    FILE - The Oct. 19, 2012 file photo shows a Novartis employee in a laboratory of Novartis in Prangins near Nyon, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.  (AP Photo/Keystone, Yannick Bailly)
    Business

    Investor pressure pushing drugmaker M&A deals

    Linda Johnson -
    April 22, 2014 11:03 pm
    0
    123...12Page 2 of 12
    LogoWashington Examiner
    Do Not Sell or Share My Personal Information
    Facebook
    Twitter
    Youtube

    NEWS

    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Washington Secrets
    • Entertainment
    • Sports

    POLICY

    • Defense
    • National Security
    • Energy
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space

    COMMENTARY

    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds

    RESTORING AMERICA

    • Patriotism & Unity
    • Faith, Freedom & Self-Reliance
    • Courage, Strength & Optimism
    • Equality, Not Elitism
    • Community & Family
    • Fairness & Justice
    • Mission
    • WATCH
    • IN FOCUS
    • NEWSLETTERS
    • MAGAZINE ARCHIVE
    • Policies and Standards
    • Terms Of Service
    • Subscription Terms of Use
    • Privacy Policy
    • Your Privacy Choices
    • Transparency In Coverage
    • Advertise
    • Subscribe
    • Contact
    • Careers
    • Staff
    • About Examiner
    • Facebook
    • Twitter